Navigation Links
Combination Therapy With ENBREL And Methotrexate Found Effective In RA Treatment

Combination therapy with anti-TNF agents (etanercept) and chemotherapy drug methotrexate has been shown to be effective in the treatment of Rheumatoid Arthritis.// Furthermore, the progression of joint damage has been considerably slowed down in over three quarters of patients. The chronic nature of the severe disabling condition necessitates the need for prevention of long-term joint damage in addition to conventional treatment measures.

ENBREL is the only soluble tumor necrosis factor (TNF) receptor approved to reduce signs and symptoms, induce major clinical response, improve physical function, and inhibit the progression of structural damage in patients with moderately to severely active rheumatoid arthritis (RA). ENBREL can be used alone or in combination with methotrexate.

Tumor necrosis factor (TNF) is a substance that is produced by the immune system. People with different forms of arthritis such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis have elevated levels of TNF in their body. The drug ENBREL is designed to block the effect of TNF, thereby enabling treatment.

The drug combination was found to be superior when compared to either of the monotherapy forms. A comparison of the combination therapy, ENBREL monotherapy and methotrexate monotherapy revealed that ENBREL monotherapy had significant results when compared to monotherapy with methotrexate alone.

In addition, the improvement in physical function was significantly higher in the ENBREL combination group than for either therapy alone. The improvement in the health status was 56% in the group of patients treated with combination in comparison to 37 % mean improvement in patients treated with ENBREL alone and 33 % mean improvement in patients treated with methotrexate alone.

Nearly 686 patients were taken up for the study and were randomized into the three categories. Patients received either ENBREL (25 mg twice weekly), methotrexate (up to 20 mg once weekly), or ENBREL (25 mg twice weekly) plus methotrexate once weekly. The patients were assessed radiologically to determine the extent of joint damage. Changes in total erosions, changes in total joint space narrowing, numbers of eroded joints were amongst the various factors assessed. A considerable improvement was noted in the combination group. The tolerability was also much higher.

With more and more studies revealing the different options available for rheumatoid arthritis, choosing the right treatment is simply left to the clinical condition of the patient and the physician’s opinion.
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Combination Therapy Found To Improves Stroke Recovery
10. Combination Therapy Found To Be More Effective In Treating Brain Cancer
11. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: